Table 4 Summary of laboratory markers of severe COVID-19 (efficacy population)
Parameter | Comparison | Point estimate | 90% CI |
|---|---|---|---|
D-dimer | Eclitasertib vs. placebo on Day 7 | 0.88 | (0.63 to 1.21) |
| Â | Eclitasertib vs. placebo at EoT | 1.07 | (0.73 to 1.58) |
Leukocytes | Eclitasertib vs. placebo on Day 7 | 0.87 | (0.73 to 1.03) |
| Â | Eclitasertib vs. placebo at EoT | 1.03 | (0.86 to 1.23) |
Lymphocytes | Eclitasertib vs. placebo on Day 7 | 1.02 | (0.75 to 1.38) |
| Â | Eclitasertib vs. placebo at EoT | 1.03 | (0.78 to 1.37) |
Neutrophils/Lymphocytes (ratio) | Eclitasertib vs. placebo on Day 7 | 0.65 | (0.42 to 1.00) |
| Â | Eclitasertib vs. placebo at EoT | 0.67 | (0.44 to 1.02) |
Ferritin | Eclitasertib vs. placebo on Day 7 | 0.96 | (0.78 to 1.19) |
| Â | Eclitasertib vs. placebo at EoT | 0.98 | (0.77 to 1.24) |
Lactate dehydrogenase | Eclitasertib vs. placebo on Day 7 | 0.80 | (0.70 to 0.92) |
| Â | Eclitasertib vs. placebo at EoT | 0.85 | (0.75 to 0.97) |